Optic Neuropathy Market Size, Share, Analysis, Industry Report and Forecast 2022-2028
The global optic neuropathy market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Optic neuropathy is a condition that causes the optic nerves to degenerate. Despite the fact that most optic nerve problems are inherited, some emerge over time. This is one of the most common causes of serious visual impairment or blindness in middle-aged and older persons. Over the next few years, technological developments in the treatment of optic neuropathy, combined with the availability of alternative medications, are expected to propel the market growth.
To Request a Sample of our Report on Optic Neuropathy
Market: https://www.omrglobal.com/request-sample/optic-neuropathy-market
The key companies operating in the industry are
highly inclined towards the adoption of different growth strategies including
partnerships and collaborations, mergers and acquisitions, geographical
expansion, new product launches, to remain competitive in the marketplace. For
instance, The FDA granted Mitotech orphan drug status for Visomitin, a topical
therapy for Leber hereditary optic neuropathy, in December 2021. Visomitin
(SkQ1) exhibited continuous visual acuity improvement in patients with Leber
hereditary optic neuropathy across several years in a phase 2a research (LHON).
In 2022, Mitotech plans to start a phase 2 trial looking at Visomitin in
patients with LHON. According to Neurophth Therapeutics, the European Medicines
Agency granted orphan drug designation to NR082, a gene therapy medication
candidate for the treatment of Leber hereditary optic neuropathy, in January
2022. According to a separate announcement, the FDA recently approved an
experimental new drug application for NR082 for the treatment of Leber
hereditary optic neuropathy linked with the ND4 mutation. Enrollment in
clinical trials in the United States is expected to begin this year. Three
investigator-initiated trials confirmed the therapy's safety and efficacy, with
one trial demonstrating clinical persistence of up to 90 months. The FDA
designated NR082 as an orphan drug in 2020.
Market Coverage
·
The market number available for – 2021-2028
·
Base year- 2021
·
Forecast period- 2022-2028
Segment Covered-
·
By Product
·
By End-User
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape- Eli, Lilly & Co., and Pfizer Inc., among
others.
(Get 15% Discount on Buying this Report)
A
full Report of Optic Neuropathy Market is Available @ https://www.omrglobal.com/industry-reports/optic-neuropathy-market
Global Optic Neuropathy Market Report by Segment
By Product Type
·
BA-240
·
IWP-953
·
LM-22A4
·
Others
By End-User
·
Specialty Clinics
·
Hospitals
·
Others
Global Optic Neuropathy Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries
are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other research-based
services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment